Comparison of the Effects of N-acetylcysteine, Calcium Hydroxide, and Double Antibiotic Paste

NCT ID: NCT07340944

Last Updated: 2026-01-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-10
• Study Completion Date: 2024-05-15

Brief Summary

This study aimed to evaluate the efficacy of N-acetylcysteine (NAC) used as an intracanal medicament on antibacterial activity, periapical RANKL/OPG ratio, and postoperative pain levels.

Detailed Description

Apical periodontitis (AP) is a condition characterized by a dominant inflammatory response in the root canal system of the affected tooth and irreversible inflammation of the periradicular tissues caused by a microbial infection . Endodontic treatment is considered the gold standard treatment for apical periodontitis because it completely removes the pulp tissue and biofilm. During this process, lesions that may occur in the periradicular tissues due to endodontic origin can be minimized, reduced, or completely eliminated .

Numerous irrigation protocols and intracanal medications, including various mechanical instrumentation techniques, have been developed to reduce microorganisms and inflammation in the root canal system and to control pain . Intracanal medications are antibacterial agents placed within the root canal between sessions to eliminate residual microorganisms . These medications exhibit anti-inflammatory effects, thereby reducing pain, eliminating apical exudate, controlling inflammatory root resorption, and preventing contamination between sessions . However, numerous published articles on endodontic infection control debate the effectiveness of existing intracanal drugs These conflicting findings complicate the determination of an ideal intracanal drug for endodontic treatments and have led researchers to search for more effective and reliable alternatives.

N-acetylcysteine (NAC), a sulfhydryl group-containing compound with mucolytic properties, was first patented in 1960 and began to be used in medicine in 1967 . In recent years, it has been evaluated as a potential agent as an irrigating solution and intracanal medicament in endodontics. Numerous in vitro studies on the antimicrobial activity of NAC have demonstrated its high antimicrobial activity against planktonic microorganisms and multispecies biofilms responsible for endodontic infections, including Enterococcus faecalis . In addition to inhibiting the production and release of proinflammatory cytokines , it is a potent thiol-containing antioxidant with high antimicrobial activity. Furthermore, one of the limited clinical studies on the use of NAC as an intracanal medication reported significantly increased levels of the pro-resolving lipid mediators RvE1 and RvD2 in the periapical tissues of teeth treated with NAC as an intracanal medication, whereas a similar increase was not observed in the calcium hydroxide (Ca(OH)₂)-treated group . These findings demonstrate that NAC is not only noteworthy for its antimicrobial activity but also for its biological properties that may contribute to the resolution of the inflammatory response.Antimicrobial activity alone is not sufficient to assess the clinical efficacy of intracanal medicaments; the biological effects of these agents on periapical tissues should also be considered. In this context, the Nuclear factor kappa-B receptor activator ligand (RANKL)/Osteoprotegerin (OPG) ratio, a key indicator of osteoclastic activity, is a valuable biomarker for biochemically assessing treatment response in endodontic treatments because it reflects the effect of inflammation on bone destruction. Increasing RANKL levels and decreasing OPG levels have been associated with root-end resorption and periapical lesion progression. Furthermore, postoperative pain, which directly impacts patients' quality of life, is one of the key criteria for evaluating the clinical success of intracanal medications. Therefore, this study aimed to conduct a holistic analysis of intracanal medicaments from both biological and clinical perspectives by evaluating not only antimicrobial activity but also the RANKL/OPG ratio and postoperative pain levels.

To date, there are no randomized controlled trials using NAC as an intracanal medication, where each of its antibacterial activity, RANKL/OPG ratio, and effect on postoperative pain levels has been clinically evaluated. This study, which is the first to examine these three parameters separately at the clinical level, aims to evaluate the effects of NAC on postoperative pain, antibacterial activity, and the RANKL/OPG ratio by comparing it with Ca(OH)₂ and double antibiotic paste (DAP). For this purpose, our study aims to test the null hypothesis that NAC, Ca(OH)₂, and DAP used as intracanal medications have no effect on antibacterial activity, RANKL/OPG ratio, or postoperative pain levels.

Conditions

Chronic Apical Periodontitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

N-acetylcysteine group

NAC was placed into the root canal as an intracanal medication.

Group Type: EXPERIMENTAL

N Acetyl Cysteine

Intervention Type: DRUG

NAC was placed into the root canal as an intracanal medication. The medication was removed after one week. Root canal treatment was completed. Treatment was completed for 15 patients in the group within one month.

Calcium Hydroxide Group

Ca(OH)2 was placed into the root canal as an intracanal medication.

Group Type: ACTIVE_COMPARATOR

Calcium Hydroxide (Ca(OH)2)

Intervention Type: DRUG

Ca(OH)2 was placed into the root canal as an intracanal medication. The medication was removed after one week. Root canal treatment was completed. Treatment was completed for 15 patients in the group within one month.

Double Antibiotic Paste Group

DAP was placed into the root canal as an intracanal medication.

Group Type: ACTIVE_COMPARATOR

Double Antibiotic Paste

Intervention Type: DRUG

DAP was placed into the root canal as an intracanal medication. The medication was removed after one week. Root canal treatment was completed. Treatment was completed for 15 patients in the group within one month.

Interventions

N Acetyl Cysteine

NAC was placed into the root canal as an intracanal medication. The medication was removed after one week. Root canal treatment was completed. Treatment was completed for 15 patients in the group within one month.

Intervention Type: DRUG

Calcium Hydroxide (Ca(OH)2)

Ca(OH)2 was placed into the root canal as an intracanal medication. The medication was removed after one week. Root canal treatment was completed. Treatment was completed for 15 patients in the group within one month.

Intervention Type: DRUG

Double Antibiotic Paste

DAP was placed into the root canal as an intracanal medication. The medication was removed after one week. Root canal treatment was completed. Treatment was completed for 15 patients in the group within one month.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Non-vital teeth confirmed by clinical and pulp sensitivity tests
• Teeth with a single canal and diagnosed with asymptomatic apical periodontitis
• Periapical assessment (PAI) of 2 or greater
• Teeth with a pocket depth not exceeding 3 mm
• Teeth without excessive root curvature (Schneider class 1) and with visible root canals on radiographs
• Permanent teeth with complete root development
• Patients between the ages of 18 and 65
• Teeth without previous endodontic treatment

Exclusion Criteria

• Patients who refused to participate in the study
• Patients with any systemic disease
• Patients who received antibiotic treatment within the last 3 months
• Patients who were pregnant or suspected of being pregnant
• Teeth with excessive crown damage that would not allow for the placement of a rubber dam
• Teeth with root fractures, pathological findings or mobility,
• Presence of any resorption in the involved tooth,
• Patients with active swelling and tenderness to palpation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ataturk University

OTHER

Sponsor Role: lead

Responsible Party

Ceren Yeniay

PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ceren Yeniay

Role: PRINCIPAL_INVESTIGATOR

Ataturk University

Locations

Ataturk University

Erzurum, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

AU-DF-CY-01

Identifier Type: -

Identifier Source: org_study_id